The De-Rating

The De-Rating

At $58.30 Maximus trades at 6.9 times forward adjusted earnings, about six times forward adjusted EBITDA, and a 15.5% forward free-cash-flow yield — roughly half the 17-to-20-times earnings multiple it held for most of the prior decade. The 41% fall since January 2026 is a de-rating, not an earnings decline: management raised fiscal 2026 guidance twice while the stock dropped. Whether that is cheap turns on the durability the earlier chapters weighed, not on the current numbers, which are at records.

What the price implies

Discounted at 10%, Maximus's $58.30 price implies free cash flow declining about 5% a year in perpetuity, yet its direct 2025 federal-efficiency hit was about $4 million (0.07% of revenue) and it raised earnings guidance twice while peers ICF and SAIC absorbed 25% and roughly 3% revenue declines, while free cash flow merely holding flat would support about $90 a share [1] [2] [3].

The arithmetic behind that sentence is a reverse discounted-cash-flow read. Fiscal 2026 free cash flow at the $475 million midpoint is about $9.00 a share on 52.5 million shares [4]. Discounting that stream as a perpetuity at a 10% required return, the current $58.30 is consistent with free cash flow shrinking about 5% a year, forever. If instead it merely holds flat, the same discounting supports roughly $90 a share; low-single-digit growth supports more.

Source: derived from the fiscal 2026 free-cash-flow midpoint of $475M [5] and 52.5 million shares [6]; Gordon-growth perpetuity at a 10% discount rate.

The scenario the range is most sensitive to is the long-run growth rate, and that rate is downstream of two things the earlier chapters already examined: whether the essential-program franchise survives its recompetes (Recompete Durability) and whether the record margins hold once the fading volume bulge clears (Operating Leverage). A reader who accepts those chapters' calibrated read — revenue probably higher a decade out, margins structurally lifted — would put the durable path in the flat-to-growing band, where the arithmetic points well above the price. A reader who does not would note that the market is not pricing collapse: a slow decline, not a wind-down, and one that may be rational rather than fearful. SAIC has guided fiscal 2027 revenue to a further organic decline it attributes mainly to recompete losses [7], and Maximus faces its own concentrated recompete when the veterans-exam contract closes to all vendors on December 31, 2026 [8] — so the priced-in fade may reflect a rational, recompete-driven markdown of terminal value rather than fear. The gap between the two paths, roughly $58 versus $90-plus, is the investment case. The discount rate matters too but less: at a 9% required return the flat-free-cash-flow value rises to about $100, at 11% it falls to about $82.

Two honest haircuts sit inside the $475 million base. Part of fiscal 2024–25 profitability rode roughly three points of non-recurring volume that management is removing from the fiscal 2026 guide (Operating Leverage), and a normalised free-cash-flow figure nearer $400 million would lower every value in the table by about 15% — flat free cash flow then supports roughly $76 rather than $90. Even on that stricter base the price still implies a perpetual decline of around 3% a year.

A drawdown, not an earnings decline

Maximus peaked at $98.93 on January 22, 2026 and trades at $58.30, a 41% decline that erased roughly $2.4 billion of market value in under six months. Over the same window the business did not deteriorate. Fiscal 2025 closed with record adjusted EBITDA of $701.6 million (a 12.9% margin) and diluted earnings of $5.51 a share [9]. Then, as the price fell, management raised fiscal 2026 adjusted-EPS guidance in February to $8.05–$8.35 [10] and again in May to $8.25–$8.55 [11]. Earnings estimates rose while the equity repriced down by nearly half.

Sources: daily price series, as reported; FY2025 diluted EPS and FY2026 free-cash-flow guidance [12]; [13].

The clearest way to see the de-rating is the earnings multiple itself. For nine straight fiscal years through 2025, Maximus's stock closed the September fiscal year at 16.6 to 20.8 times trailing GAAP earnings — the single outlier, 28 times in 2023, reflected a temporarily depressed denominator during the post-pandemic margin trough, not an expensive stock. At $58.30 against fiscal 2025's $5.51, the trailing multiple is 10.6 times, close to half its own decade norm.

Source: derived from the daily price series and reported diluted EPS, FY2017–FY2025 Form 10-Ks; current multiple uses $58.30 over FY2025 EPS of $5.51 [14].

What the price pays for

On every metric that matches this cash-generative, lightly capitalised model, the stock screens cheap in absolute terms. Adjusted earnings of $7.36 for fiscal 2025 put the trailing adjusted multiple at 7.9 times; the raised fiscal 2026 midpoint of about $8.40 puts the forward multiple at 6.9 times [15]. Enterprise value — the $3.06 billion equity plus $1.38 billion of net debt at March 31, 2026 — is $4.44 billion, or 6.3 times trailing adjusted EBITDA and under six times the fiscal 2026 guide.

Sources: price and net debt as reported; FY2025 actuals and FY2026 guidance [16]; [17].

These numbers clear the hurdles a free-cash-flow buyer sets by a wide margin. Trailing free cash flow of $366 million against a $3.06 billion market capitalisation is a 12.0% yield; the fiscal 2026 guide of $450–500 million lifts the forward yield to about 15.5% [18]. Enterprise value at 6.3 times EBITDA sits far below the 12-times line at which the multiple alone would look full. The one qualifier a balance-sheet-first investor would flag is leverage: at roughly 1.9 times net debt to EBITDA this is not the net-cash balance sheet such a buyer prefers, though it is inside the tolerance a high free-cash-flow yield earns.

The cash behind the yield

The forward 15.5% yield is real but back-end-loaded, and that is the strongest fact against reading it as a clean run-rate. It requires operating cash flow to climb from $429 million in fiscal 2025 toward the $490–540 million embedded in the guide, and the first half of fiscal 2026 ran the other way: a $251 million free-cash-flow outflow in the December quarter, recovered only partly by $179 million in the March quarter, for a negative first half [19] [20]. The guide leans on a large second-half collection catch-up, the same September-quarter pattern that produced $642 million of free cash flow in the fourth quarter of fiscal 2025 [21]. It is also partly financed: the receivables-purchase facility and the collection timing behind the headline cash are dissected in the report's cash chapter (Cash Conversion). The point for valuation is narrow — the multiple looks low in part because a share of the cash it capitalises is timing-dependent, not because the market has missed it.

External marks and what would change the read

The thinnest external cross-check points the other way. The two analysts who publish targets carry a mean of $105 against the $58.30 price, both rated buy — but two estimators is scant coverage, and the targets have not repriced for the federal-budget and recompete fears that drove the fall, so this is weak corroboration, not confirmation. On tradability, the stock itself clears a value investor's size test comfortably: about $47 million changes hands daily and annual turnover runs above 250%, so a meaningful position is executable. The implied-volatility and long-dated-options questions a derivatives overlay would ask sit outside the filing record and need a market-data source; the closing chapter is the place to resolve them.

The measured read is that the drawdown is predominantly a de-rating of terminal value rather than a markdown of current cash flow: near-term earnings and free cash flow rose across the very months the multiple halved, and the price now implies a slow perpetual decline that the durability and margin chapters argue is more pessimistic than the evidence supports — while conceding the market is pricing a real, not imaginary, risk. What would change that read is checkable and dated: the outcome of the December 31, 2026 veterans-exam recompete, which sits under both the revenue and the margin at risk, and whether the second half of fiscal 2026 delivers the collection catch-up the free-cash-flow guide requires. Confirmation of either erosion would move the durable path from the flat-to-growing band toward the decline the price already assumes.